IN VIVO EVALUATION OF QUINAPRIL TRILAYERED MATRIX TABLETS

Authors

  • ASHWIN K Department of Pharmacy, Mewar University, Chittorgarh, Rajasthan, India.
  • RAMA MOHAN REDDY T Department of Pharmacy, Mewar University, Chittorgarh, Rajasthan, India.

DOI:

https://doi.org/10.22159/ajpcr.2021.v14i7.42002

Keywords:

Quinapril, Hypertension, Hydroxypropyl methylcellulose, Release order kinetics, Pharmacokinetic studies

Abstract

Objective: The aim was to design, formulate, and evaluate the trilayer matrix tablets incorporated with quinapril for extend drug release.

Methods: Quinapril trilayer matrix tablets were formulated using design of experiment software wherein initially 27 formulations (QF1-QF27) were designed for active layer from which one best formulation was chosen based on drug content, swelling index and in vitro release studies. The chosen formulation was formulated into extended release trilayed matrix tablet by varying proportions of polymers by direct compression and was evaluated for various physicochemical parameters, drug release. Best formulation was characterized for Fourier transform infrared (FTIR), stability, and pharmacokinetic study.

Results: Out of 27 formulations highest drug release was exhibited by QF16 (98.85%) which was formulated into trilayer matrix tablets (AQF16- HQF16). Out of which EQF16 was found to exhibit highest values with 98.42% swelling index, 99.56% drug content, and 99.72% drug release in 24 h. All quinapril trilayer formulations showed zero-order and first-order for marketed product. The optimized formulation EQF16 was found to exhibit no interaction with excipients interpreted by FTIR and no significant changes were observed after loading for stability. In vivo studies conducted using optimized formulation EQF16 attained peak drug concentration (Tmax) of 4.0±0.06 and 1.0±0.03 h for the optimized and commercial formulations, respectively, while mean maximum drug concentration (Cmax) was 302.64±0.07 ng/mL and was significant (p<0.05) as compared to the quinapril marketed product formulation 358.78±0.75 ng/mL.

Conclusion: Hence, quinapril was successfully formulated into trilayer matrix tablet and found to be stable.

Downloads

Download data is not yet available.

References

Ho-Wah H, Robinson J, Lee V. Design and fabrication of oral controlled release drug delivery systems. In: Controlled Drug Delivery. New York: Marcell Dekker Inc.; 1987. p. 373. DOI: https://doi.org/10.1201/b14193-12

Conte U, Maggi L. Multi-layer tablets as drug delivery devices. Pharm Technol 1998;2:18-25.

Kitt J. New approaches in hypertension management: A review of current and developing technologies and their potential impact on hypertension care. Curr Hypertens Rep 2019;21:44. DOI: https://doi.org/10.1007/s11906-019-0949-4

Syed IA, Mangamoori LN, Rao YM. Formulation and characterization of matrix and triple-layer matrix tablets for controlled delivery of metoprolol tartrate. Int J Pharm Sci Drug Res 2011;3:23-8.

Gohel MC, Bariya SH. Hypromellose and polyethylene oxide: Comparative formulation design of triple-layer tablets. J Pharm Res 2010;3:2223-7.

Srinivas MP, Chaitanya N. Formulation and evaluation of sitagliptin phosphate and metformin hydrochloride trilayered tablets. Int J Drug Deliv 2013;5:15-27.

Efentakis M, Peponaki C. Formulation study and evaluation of matrix and three-layer tablet sustained drug delivery systems based on carbopols with isosorbite mononitrate. AAPS PharmSci Tech 2008;9:917-23. DOI: https://doi.org/10.1208/s12249-008-9084-2

Krishnaiah YS, Karthikeyan RS, Bhaskar P, Satyanarayana V. Bioavailability studies on guar gum-based three-layer matrix tablets of trimetazidine dihydrochloride in human volunteer. J Control Release 2002;83:231-9. DOI: https://doi.org/10.1016/S0168-3659(02)00215-8

Lordi NG. Sustained release dosage forms. In: The Theory and Practice of Industrial Pharmacy. 3rd ed. Mumbai: Varghese Publishing House; 2008. p. 430-54.

Patil R, Vishal, P, Sonawane R. Nano and microparticulate chitosan based system for formulation of carvedilol rapid melt tablet. APB 2015;5:169-79. DOI: https://doi.org/10.15171/apb.2015.024

Talukdar MM, Mooter VD, Augustijns P, Maga TT, Verbeke N, Kinget R. In vitro evaluation of guar gum as potential excipients for oral controlled release matrix tablet formulation. Int J Pharm 1998;169:10513. DOI: https://doi.org/10.1016/S0378-5173(98)00112-4

Yang L, Fassihi R. Accessibility of solid core tablet for dissolution in a asymmetric triple-layer matrix system. J Pharm Pharmcol 2003;55:1331. DOI: https://doi.org/10.1211/0022357021927

Karadag E. In vitro swelling studies and preliminary biocompatibility evaluation of acrylamide-based hydrogels. Biomaterials 1996;17:67-7. DOI: https://doi.org/10.1016/0142-9612(96)80757-5

Bozal-Palabiyik B, Uslu B, Ozkan Y, Ozkan SA. In-vitro drug dissolution studies in medicinal compounds. Curr Med Chem 2018;25:4020-36. DOI: https://doi.org/10.2174/0929867325666180322145335

Chidambaram N, Porter W, Flood K, Qiu Y. Formulation and characterization of new layered diffusion matrices for zero-order systained release. J Control Release 1998;52:149-58. DOI: https://doi.org/10.1016/S0168-3659(97)00207-1

Sharma PR, Lewis SA. Design and in vitro/in vivo evaluation of extended-release matrix tablets of nateglinide. J Young Pharm 2013;5:167-72. DOI: https://doi.org/10.1016/j.jyp.2013.11.003

Altunsoy S, Bozal-Palabiyik B, Uslu B. Validation of liquid chromatographic method for simultaneous determination of quinapril and hydrochlorothiazide in pharmaceutical dosage forms. Turk J Pharm Sci 2013;10:255-62.

Published

07-07-2021

How to Cite

K, A., and R. M. REDDY T. “IN VIVO EVALUATION OF QUINAPRIL TRILAYERED MATRIX TABLETS”. Asian Journal of Pharmaceutical and Clinical Research, vol. 14, no. 7, July 2021, pp. 117-25, doi:10.22159/ajpcr.2021.v14i7.42002.

Issue

Section

Original Article(s)